M. Kulyk & Associates LLC Has $338,000 Stake in Abbott Laboratories (NYSE:ABT)

M. Kulyk & Associates LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 22.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,986 shares of the healthcare product maker’s stock after selling 852 shares during the period. M. Kulyk & Associates LLC’s holdings in Abbott Laboratories were worth $338,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Impax Asset Management Group plc grew its holdings in Abbott Laboratories by 0.5% in the 3rd quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock valued at $63,573,000 after buying an additional 2,754 shares during the last quarter. Summit Global Investments grew its holdings in Abbott Laboratories by 13.4% in the 3rd quarter. Summit Global Investments now owns 4,103 shares of the healthcare product maker’s stock valued at $468,000 after buying an additional 486 shares during the last quarter. Leavell Investment Management Inc. grew its holdings in Abbott Laboratories by 1.3% in the 3rd quarter. Leavell Investment Management Inc. now owns 36,401 shares of the healthcare product maker’s stock valued at $4,150,000 after buying an additional 460 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at approximately $1,044,000. Finally, United Bank grew its holdings in Abbott Laboratories by 1.8% in the 3rd quarter. United Bank now owns 27,284 shares of the healthcare product maker’s stock valued at $3,111,000 after buying an additional 488 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. The Goldman Sachs Group raised their target price on Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. StockNews.com downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. UBS Group raised their price objective on Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, Barclays reiterated an “overweight” rating and issued a $158.00 price objective (up previously from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Four analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $137.19.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at approximately $16,152,064.50. This trade represents a 15.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares of the company’s stock, valued at $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,449 shares of company stock worth $15,463,316. 1.10% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $137.23 on Friday. The business has a 50 day simple moving average of $125.35 and a 200 day simple moving average of $118.76. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The company has a market capitalization of $238.00 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 2.52 and a beta of 0.70.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. During the same quarter in the previous year, the company posted $1.19 EPS. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.72%. Abbott Laboratories’s payout ratio is 30.85%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.